

Guidance on World Health Organization (WHO) Approved COVID-19 Vaccines

Revision Date: September 27, 2023

This policy is evergreen and will be updated as new information becomes available.

WHO Approved Primary Series (Note: A COVID-19 vaccine primary series may differ for immunocompromised individuals)
(Non-Health Canada approved but accepted by the Government of Canada and Alberta)

Vaccines	Dose(s)/Interval
Sinovac (Sinovac Life Science Co., Ltd.)	2 doses with at least 14 days between doses
Sinopharm (SinoPharm Beijing Institute of Biological Products)	2 doses with at least 21 days between doses
Covaxin (Bharat Biotech, India)	2 doses with at least 28 days between doses
Covovax (Serum Institute of India under license from Novavax)	2 doses with at least 21 days between doses
Convidecia (CanSino Biologics, China)	1 dose

Note:

- For children who have received one or more doses of a WHO vaccine see [Management of COVID-19 Vaccine Administration Errors and Deviations](#) for validity of doses administered to individuals 17 years of age and younger.